Exagen (NASDAQ: XGN) releases Q3 and nine-month 2025 financial results

Rhea-AI Filing Summary

Exagen Inc. filed a current report to note that it has released its financial results for the three and nine months ended September 30, 2025. The company issued a press release on November 4, 2025, which is attached as Exhibit 99.1 and provides the detailed figures and commentary on its results of operations and financial condition.

The report clarifies that the earnings information and the press release are being furnished rather than filed, meaning they are not subject to certain Exchange Act liabilities and are not automatically incorporated into other securities law filings unless specifically referenced.

0001274737FALSE00012747372025-11-042025-11-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2025

EXAGEN INC.

(Exact name of registrant as specified in its charter)

Delaware

001-39049

20-0434866

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

1261 Liberty Way

Vista, CA 92081

(Address of principal executive offices) (Zip Code)

(760) 560-1501

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

XGN

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 4, 2025, the Company reported its financial results for the three and nine months ended September 30, 2025. A copy of the press release issued by the Company is furnished as Exhibit 99.1 to this report.

The information furnished with Item 2.02 of this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filings under the Exchange Act or under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press Release dated November 4, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXAGEN INC.

Date: November 4, 2025

By:

/s/ Jeffrey G. Black

Jeffrey G. Black

Chief Financial Officer

FAQ

What did Exagen Inc. (XGN) disclose in this 8-K?

Exagen Inc. disclosed that it reported its financial results for the three and nine months ended September 30, 2025, via a press release dated November 4, 2025, furnished as Exhibit 99.1.

Which period do the latest Exagen Inc. (XGN) results cover?

The latest results cover the three and nine months ended September 30, 2025.

Where can investors find the detailed Q3 2025 results for Exagen Inc. (XGN)?

Detailed results are contained in the press release dated November 4, 2025, which is attached to the report as Exhibit 99.1.

Are Exagen Inc. (XGN) Q3 2025 results considered filed with the SEC?

No. The company states that the information provided under Item 2.02, including Exhibit 99.1, is being furnished and not deemed filed for purposes of Section 18 of the Exchange Act.

Who signed the Exagen Inc. (XGN) report on the Q3 2025 results?

The report was signed on behalf of Exagen Inc. by Jeffrey G. Black, the company’s Chief Financial Officer.

What exhibits are included with Exagen Inc. (XGN)’s November 4, 2025 report?

The report includes Exhibit 99.1, the press release dated November 4, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.